[1]
StanisicS., BertolottoA., BertoP., Di ProcoloP., and MorawskiJ., “The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy”, GRHTA, vol. 6, no. 1, Apr. 2019.